Immunophotonics Switzerland (IPS Biopharma AG)
|Country:||Switzerland and USA|
|Category:||Clinical Stage Developemt Company|
|Speaker:||Dr. Theresa Visarius|
Immunophotonics Switzerland (IPS Biopharma AG) is a privately owned biotech with an innovation to combat solid metastatic cancers. The company is in phase 2a clinical development of its first asset IP-001, designed to induce tumor-specific immune activation. A single intratumoral injection of IP-001 can ignite a systemically active cancer immunotherapy able to target distant untreated metastases. IP-001 also shows notable promise as a vaccine adjuvant in infectious disease.